Cohort event monitoring for safety signal detection in adult individuals 18 years and above after immunisation with coronavirus disease 2019 vaccines in Nigeria

Introduction: In Nigeria, immunisation with coronavirus disease 2019 (COVID-19) vaccines commenced in March 2021. COVISHIELD from AstraZeneca (AZ), a viral vector vaccine, was the brand administered in the first phase of vaccinations for pre-determined eligible adults 18 years and above. As more bra...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The Nigerian postgraduate medical journal Ročník 30; číslo 1; s. 18 - 24
Hlavní autoři:	Osibogun, Akinsanya, Shuaib, Faisal, Adeyeye, Christianah, Onajole, Adebayo, Ejembi, Clara, Banwat, Mathilda, Wright, Kikelomo, Mohammed, Abdullahi, Adeleye, Omokhoa, Yahya, Shuaib, Ifeadike, Chigozie, Elemuwa, Uchenna, Bassey, Bassey, Oluwole, Esther, Erinoso, Olufemi
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Nigeria Wolters Kluwer India Pvt. Ltd 01.01.2023 Medknow Publications and Media Pvt. Ltd Medknow Publications & Media Pvt. Ltd Wolters Kluwer Medknow Publications
Témata:	Adult adverse events ChAdOx1 nCoV-19 Cohort Studies coronavirus Coronaviruses COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - adverse effects Hospitalization Humans Immunization Methods Middle Aged Mortality Nigeria Pandemics - prevention & control Patient monitoring reactogenicity Vaccination vaccines Viral Vaccines - adverse effects Nigeria coronavirus Adverse events vaccines reactogenicity
ISSN:	1117-1936, 2468-6875
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!